Disclosed is a melanoma vaccine comprising: at least one dendritic cell from a subject that has melanoma, wherein the at least one dendritic cell has been contacted in vitro with at least one melanoma tumour cell from the same subject, wherein the melanoma tumour cell has been treated in vitro with interferon-gamma (IFN-gamma) or with an IFN-gamma mimetic, and further wherein the at least one melanoma tumour cell is non-dividing, autophagic, and non-apoptotic. Also disclosed is the use of the above-described melanoma vaccine in the manufacture of a medicament for stimulating an immune response against a melanoma-specific antigen in a subject with melanoma.
